ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Natural killer (NK) cells and rheumatoid arthritis (RA)"

  • Abstract Number: 2602 • 2016 ACR/ARHP Annual Meeting

    Anti-TNF Therapy Is Associated with an Impaired Function of NK Cells and a Defective Immunosurveillance Against B-Cell Lymphomas

    Gaetane Nocturne1,2, Bineta Ly3, Saida Boudaoud4, raphaèle seror5,6, Laurence Zitvogel7 and Xavier Mariette8,9, 1Rheumatology Service, Bicêtre University Hospital, Le Kremlin Bicetre, France, 2INSERM U1184, Université Paris Sud, Le Kremlin Bicêtre, France, 3INSERM U1184, Paris Sud University, Kremlin Bicetre, France, 4INSERM U1184, Paris Sud University, Le Kremlin Bicêtre, France, 5Assistance Publique-Hôpitaux de Paris (APHP), Hôpitaux universitaires Paris Sud, Université Paris Sud, kremlin bicetre, France, 6INSERM U1184, Paris Sud University, Le Kremlin Bicetre, France, 7IGR - INSERM U1015, Villejuif, France, 8Department of Rheumatology, APHP - Hopitaux universitaire Paris Sud, Le Kremlin Bicetre, France, 9INSERM U1184, Université Paris-Sud, Paris, France, Le Kremlin Bicetre, France

    Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased risk of lymphoma linked to activity of the disease. Immunosuppressive drugs have been suspected to induce…
  • Abstract Number: 1499 • 2014 ACR/ARHP Annual Meeting

    Characterization of ABT-494, a Second Generation Jak1 Selective Inhibitor

    Candace Graff1, Annette Schwartz1, Jeffrey Voss2, Neil Wishart3, Lisa Olson1, Jonathon George3, Deborah Hyland3 and Heidi Camp4, 1AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, 2Immunology, AbbVie Pharmaceuticals, Worcester, MA, 3Abbvie Pharmaceuticals, worcester, MA, 41101 Oak Street, Abbvie, Winnetka, IL

    Background/Purpose  Jak kinase blockade can effectively manage rheumatoid arthritis (RA) and in some cases achieve remission. However, first generation Jak inhibitors have not met expectations…
  • Abstract Number: 2374 • 2013 ACR/ARHP Annual Meeting

    Pharmacodynamics Of a Novel Jak1 Selective Inhibitor In Rat Arthritis and Anemia Models and In Healthy Human Subjects

    Jeffrey Voss1, Candace Graff2, Annette Schwartz3, Deborah Hyland4, Maria Argiriadi4, Heidi Camp5, Lori Dowding4, Michael Friedman4, Kristine Frank5, Jonathon George4, Eric Goedken4, Gloria Lo Schiavo4, Michael Morytko4, Robert o'Brien4, Robert Padley6, Matthew Rosebraugh5, Michael Rozema5, Kent Stewart5, Grier Wallace4, Neil Wishart4, Anwar Murtaza7 and Lisa Olson3, 1Immunology, AbbVie Pharmaceuticals, Worcester, MA, 2Drug Metabolism and Pharmacokinetics, Abbvie Pharmaceuticals, worcester, MA, 3AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, 4Abbvie Pharmaceuticals, worcester, MA, 5abbvie pharmaceuticals, north chicago, IL, 6AbbVie, Inc, North Chicago, IL, 7Broad Institute, Cambridge, MA

    Background/Purpose: Anti-cytokine therapies have become the mainstay of treatment for rheumatoid arthritis (RA) disease symptoms and can arrest disease progression. Despite numerous treatment options there…
  • Abstract Number: 1158 • 2013 ACR/ARHP Annual Meeting

    Decreased NK-Cell Numbers and Upregulation Of Markers Of Systemic Inflammation In Autoantibody –Positive Arthralgia Patients and Early Rheumatoid Arthritis Patients But Not In Autoantibody-Negative Rheumatoid Arthritis Patients

    Paulina Chalan1, Johan Bijzet2, Kornelis S.M. van der Geest1, Bart-Jan Kroesen3, Annemieke M.H. Boots4,5 and Elisabeth Brouwer1, 1Dept. of Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, 2Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, 3Dept. of Laboratory Medicine, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, 4Dept. of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, 5Groningen Research initiative on healthy Ageing and Immune Longevity (GRAIL), Groningen, Netherlands

    Background/Purpose: Identification of seropositive individuals at risk for arthritis development would open opportunities for early clinical intervention. In a recent study on seropositive arthalgia patients…
  • Abstract Number: 1080 • 2012 ACR/ARHP Annual Meeting

    Effect of Anti-NKG2A Antibody Treatment On NK Cell Receptor Expression in Rheumatoid Arthritis Patients

    Joseph Wahle, John Bui and Kristen Bontadelli, Biopharmaceuticals Research Unit, Novo Nordisk, Seattle, WA

    Background/Purpose: This study explored the effect of in vitroblockade of the NKG2A HLA-E interaction on peripheral NK cells from rheumatoid arthritis patients.  To block this…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology